Draft guidance from NICE recommends durvalumab before and after surgery for muscle-invasive bladder cancer following phase 3 trial survival data.

A new Stanford Medicine study reveals that colorblind men face 52% higher bladder cancer death risk because they can't see ...

By Dr. Sanchari Sinha Dutta, Ph.D. A large electronic health record study suggests that difficulty recognizing painless blood ...

The earliest symptoms of bladder cancer may go unnoticed by patients with colorblindness or similar color vision deficiencies ...

USA: Researchers have drawn attention to an unusual but potentially distressing adverse effect linked to a commonly used postoperative treatment for non–muscle-invasive bladder cancer (NMIBC).

AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence for durvalumab, ...

Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical ...

Although bladder cancer ranks as the sixth most common cancer in the United States, with approximately 85,000 new cases diagnosed each year, it continues to receive limited awareness, advocacy, and ...

When you learn you have bladder cancer, it’s only natural to ask: "Can I survive this, for how long, and can I expect to be cured?" You may have searched online for survival rate information. These ...

What Is Zusduri Used For? Zusduri is used to treat a certain type of recurrent, persistent bladder cancer known as LG-IR-NMIBC. About 75% of people with bladder cancer present with non-muscle invasive ...

Armando, a 71-year-old with an active lifestyle, was midway through a round of golf when a strange sensation crept into his abdomen after drinking water. It was just a fleeting moment; one he brushed ...

Vinod Khanna's wife said, "It was 2001 when Vinod had a diagnosis of lung cancer" ...